The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
broker target 98 p so looks cheap down here
25p by next week news and back to 40p or more. Get ready!
I can see big buy going through now, get ready guys for 200% rise!
Going to NT to buy now but you can sell.
Alaska North Slope
Red Emperor has entered into a binding agreement that will see the company participate in the drilling of a highly prospective Nanushuk oil trend exploration well on the Alaska North Slope in early 2019, with an estimated prospective resource volume of 400 MMbbls.
The drill target is immediately adjacent to and a direct analogue of the third party Horseshoe-1/1A oil well. Horseshoe is part of the billion-barrel plus Nanushuk oil play-fairway, one of the largest conventional oil fields discovered in the US in more than 30 years.
Red Emperor’s working interest is 31.5% in the prospect leases with the company fully funded to meet its share of all work commitments associated with the farm-in agreement. Red Emperor has joined a consortium with well-funded and experienced JV partners to execute the drill programme.
The North Slope has had more than 17 billion barrels of oil discovered and produced to date, and remains a proven, extremely prolific world-class petroleum province.
Going north. One of the best plays on AIM just now imo.
Third time lucky? - https://www.proactiveinvestors.co.uk/companies/news/313612/analyst-sees--clear-rationale--for-immupharma-to-move-forward-with-lupuzor-13612.html
Video link: https://bit.ly/2RgSQtk
This was published on Jun 2019 before the last weeks mega update (92p before and now ???
The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.
https://www.youtube.com/watch?v=22p0gPNE3pk&feature=emb_logo
Nucant Program
ImmuPharma's subsidiary Elro SARL ('Elro') holds our cancer Nucant program, IPP-204106, which is focused on combination therapy approaches. ImmuPharma has reviewed different options for progressing this program and is now pursuing a divestment strategy in combination with the Group's Ureka subsidiary. A grant was awarded by the EU to different EU partners (€7 million total with €430k awarded to ImmuPharma) to develop the Nucants in combination with cytotoxic drugs linked to a solid support. The molecule has also shown promising results in ophthalmology (age-related macular degeneration) models.
Peptide Platform
ImmuPharma's subsidiary Ureka SARL ('Ureka') has been developing lead compounds from its novel and patented peptide technology platform UrelixTM. Ureka is based at the Institut Europeen de Chimie et Biologie (IECB) in Bordeaux, France which is under the joint authority of the CNRS, Inserm and the University of Bordeaux.
In January 2018, the Company announced the completion of a placing of 6,944,445 new ordinary shares of 10p each at a placing price of 144p raising a total of £10 million before expenses. The Company raised the funds in order to further strengthen the Company's financial position as negotiations continue with potential partners for Lupuzor™ and to support further investment in ImmuPharma's earlier stage portfolio.
My first post after investing here last week and manage to get in at low.
There's quite a few individual posters very negative for personal agenda and I don't want to get into debate right now.
I will update all LTH and newbies shortly why Immupharma is going to new heights after last weeks RNS.